Physician profile
Lizzy R Thomas
NPI 1255368924
$26,238.34
in general payments reported to CMS, 2019-2025
65 companies · $2,812 in 2025
The $2,812 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,580 · 2020: $2,366 · 2021: $4,346 · 2022: $4,094 · 2023: $4,442 · 2024: $3,598 · 2025: $2,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,845.49 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,461.11 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $3,135.22 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,468.27 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $1,163.96 | 2019-2025 | Arexvy, Ojjaara, Trelegy Ellipta |
| Amgen INC. | $1,113.37 | 2019-2025 | Evenity, Blincyto, Lumakras |
| E.R. Squibb & Sons, L.L.C. | $1,072.32 | 2021-2025 | Opdivo, Abecma, Reblozyl |
| Janssen Biotech, INC. | $1,026.45 | 2021-2025 | Carvykti, Rybrevant, Akeega |
| Abbvie INC. | $877.68 | 2019-2025 | Synthroid |
| Regeneron Healthcare Solutions, INC. | $846.28 | 2021-2025 | Libtayo |
| Incyte Corporation | $771.13 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Genentech USA, INC. | $691.80 | 2019-2023 | Lunsumio |
| Pfizer INC. | $537.13 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $504.77 | 2019-2023 | Keytruda |
| Lilly USA, LLC | $483.93 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $463.35 | 2019-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lizzy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.